首页> 外国专利> ENHANCEMENT OF TUMOR RESPONSE TO CHEMOTHERAPY BY ACTIVATION OF THE ASMASE/CERAMIDE PATHWAY THROUGH TIMED ADMINISTRATION OF A SHORT-ACTING ANTI-ANGIOGENIC AGENT

ENHANCEMENT OF TUMOR RESPONSE TO CHEMOTHERAPY BY ACTIVATION OF THE ASMASE/CERAMIDE PATHWAY THROUGH TIMED ADMINISTRATION OF A SHORT-ACTING ANTI-ANGIOGENIC AGENT

机译:通过短时抗血管生成药物的定时管理激活无烟/陶瓷通路,增强对化学疗法的肿瘤反应

摘要

Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemotherapeutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.
机译:公开了一种增强肿瘤对化学疗法的反应的方法,该方法包括向患有实体瘤的受试者施用能够激活ASMase的短效抗血管生成剂(AAA),从而产生所述药物敏感性增加的时间间隔。肿瘤对一种或多种化学治疗剂的治疗,然后在间隔内给予至少一种化学治疗剂。可以根据AAA对ASMase信令的短期激活来定义间隔。还公开了用于预测患有实体瘤的患者对化学治疗剂的肿瘤反应的方法,该方法将化学治疗剂对患者的ASM酶水平或活性(或神经酰胺水平)作为反应的指标。病人或基于动态IVIM的DW-MRI,以测量给药化疗药物后的灌注变化。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号